Nanoparticles for the treatment of osteoporosis

1 Departamento de Química Inorgánica y Bioinorgánica, Facultad de Farmacia. Universidad Complutense de Madrid, Instituto de Investigaci ́on Sanitaria Hospital 12 de Octubre i + 12, Plaza de Ramón y Cajal s/n, E-28040 Madrid, Spain
2 Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain

Received: , Accepted: , Published:

Topical Section: Cell and Tissue Engineering

References

1. Kanis JA, Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporosis Int 4: 368–381.

2. Beck GR, Ha SW, Camalier CE, et al. (2012) Bioactive silica-based nanoparticles stimulate bone-forming osteoblasts, suppress bone-resorbing osteoclasts, and enhance bone mineral density in vivo. Nanomed Nanotechnol Biol Med 8: 793–803.

3. Khajuria DK, Razdan R, Mahapatra DR (2011) Drugs for the management of osteoporosis: a review. Rev Bras Reumatol 51: 365–382.

4. Arcos D, Boccaccini AR, Bohner M, et al. (2014) The relevance of biomaterials to the prevention and treatment of osteoporosis. Acta Biomater 10: 1793–1805.

5. Wei D, Jung J, Yang H, et al. (2016) Nanotechnology treatment options for osteoporosis and its corresponding consequences. Curr Osteoporosis Rep 2016: 1–9.

6. Riggs BL, Melton LJ (2015) The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17: 505S–511S.

7. Mackey PA, Whitaker MD (2015) Osteoporosis: a therapeutic update. J Nurse Pract 11: 1011–1017.

8. Hernlund E, Svedbom A, Ivergård M, et al. (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the international osteoporosis foundation (IOF) and the european federation of pharmaceutical industry associations (EFPIA). Arch Osteoporosis 8: 1–115.

9. Kanis JA, McCloskey EV, Johansson H, et al. (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 24: 23–57.

10. Kim T, Singh RK, Sil M, et al. (2016) Acta biomaterialia inhibition of osteoclastogenesis through siRNA delivery with tunable mesoporous bioactive nanocarriers. Acta Biomater 29: 352–364.

11. Hodsman AB, Bauer DC, Dempster DW, et al. (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26: 688–703.

12. Weitzmann MN, Ha SW, Vikulina T, et al. (2015) Bioactive silica nanoparticles reverse age-associated bone loss in mice. Nanomed Nanotechnol Biol Med 11: 959–967.

13. Khajuria DK, Disha C, Vasireddi R, et al. (2016) Risedronate/zinc-hydroxyapatite based nanomedicine for osteoporosis. Mat Sci Eng C Mater 63: 78–87.

14. Giger EV, Castagner B, Leroux JC (2013) Biomedical applications of bisphosphonates. J Control Release 167: 175–188.

15. Iñiguez ANM, Clarke BL (2015) Bone biology, signaling pathways, and therapeutic targets for osteoporosis. Maturitas 82: 245–255.

16. Kanakaris NK, Petsatodis G, Tagil M, et al. (2009) Is there a role for bone morphogenetic proteins in osteoporotic fractures? Injury 40: S21–S26.

17. Lee D, Heo DN, Kim H, et al. (2016) Inhibition of osteoclast differentiation and bone resorption by bisphosphonate- conjugated gold nanoparticles. Sci Rep 6: 27336–27346.

18. Eriksen EF, Díez PA, Boonen S (2014) Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone 58: 126–135.

19. Black DM, Schwartz AV, Ensrud KE, et al. (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. JAMA 296: 2927–2938.

20. Dougall WC, Glaccum M, Charrier K, et al. (1999) RANK is essential for osteoclast and lymph node development. Gene Dev 13: 2412–2424.

21. Trejo CG, Lozano D, Manzano M, et al. (2010) The osteoinductive properties of mesoporous silicate coated with osteostatin in a rabbit femur cavity defect model. Biomaterials 31: 8564–8573.

22. Barry M, Pearce H, Cross L, et al. (2016). Advances in nanotechnology for the treatment of osteoporosis. Curr Osteoporosis Rep 14: 87–94.

23. Saini D, Fazil M, Ali MM, et al. (2014). Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis. Drug Deliv 7544: 1–14.

24. Ponnapakkam T, Katikaneni R, Sakon J, et al. (2014) Treating osteoporosis by targeting parathyroid hormone to bone. Drug Discov Today 19: 204–208.

25. Narayanan D, Anitha A, Jayakumar R, et al. (2013) In vitro and in vivo evaluation of osteoporosis therapeutic peptide PTH 1-34 loaded PEGylated chitosan nanoparticles. Mol Pharm 10: 4159–4167.

26. Lindsay R, Krege JH, Marin F, et al. (2016) Teriparatide for osteoporosis: importance of the full course. Osteoporosis Int 2016: 1–16.

27. Ong KL, Villarraga ML, Lau E, et al. (2010) Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine J 35: 1794–1800.

28. Carragee EJ, Hurwitz EL, Weiner BK (2011) A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11: 471–491.

29. Canalis E (2010) Update in new anabolic therapies for osteoporosis. J Clin Endocr Metab 95: 1496–1504.

30. Tokatlian T, Segura T (2010) siRNA applications in nanomedicine. Wires Nanomed Nanobi 2: 305–315.

31. Guo B, Wu H, Tang T, et al. (2012) A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med 18: 307–314.

32. Lin JH (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone 18: 75–85.

33. Aoki K, Alles N, Soysa N, et al. (2012) Peptide-based delivery to bone. Adv Drug Deliver Rev 64: 1220–1238.

34. Cenni E, Granchi D, Avnet S, et al. (2008) Biocompatibility of poly(d,l-lactide-co-glycolide) nanoparticles conjugated with alendronate. Biomaterials 29: 1400–1411.

35. Choi SW, Kim JH (2007) Design of surface-modified poly(d,l-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. J Control Release 122: 24–30.

36. Xinluan W, Yuxiao L, Helena NH, et al. (2015) Systemic drug delivery systems for bone tissue regeneration-a mini review. Curr Pharm Design 21: 1575–1583.

37. Yokogawa K, Miya K, Sekido T, et al. (2001) Selective delivery of estradiol to bone by aspartic acid oligopeptide and its effects on ovariectomized mice. Endocrinology 142: 1228–1233.

38. Pignatello R (2011) PLGA-alendronate conjugate as a new biomaterial to produce osteotropic drug nanocarriers. Biomaterials Applications for Nanomedicine. InTech.

39. Heller DA, Levi Y, Pelet JM, et al. (2013) Modular "click-in-emulsion" bone-targeted nanogels. Adv Mater 25: 1449–1454.

40. Willson TM, Henke BR, Momtahen TM, et al. (1996) Bone targeted drugs 2 synthesis of estrogens with hydroxyapatite affinity. Bioorg Med Chem Lett 6: 1047–1050.

41. Yarbrough DK, Hagerman E, Eckert R, et al. (2010) Specific binding and mineralization of calcified surfaces by small peptides. Calcified Tissue Int 86: 58–66.

42. Carrow JK, Gaharwar AK (2015) Bioinspired polymeric nanocomposites for regenerative medicine. Macromol Chem Phys 216: 248–264.

43. Lee MS, Su CM, Yeh JC, et al. (2016) Synthesis of composite magnetic nanoparticles Fe₃O₄ with alendronate for osteoporosis treatment. Int J Nanomed 11: 4583–4594.

44. Kedmi R, Ben-Arie N, Peer D (2010) The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. Biomaterials 31: 6867–6875.

45. Hwang SJ, Lee JS, Ryu TK, et al. (2016) Alendronate-modified hydroxyapatite nanoparticles for bone-specific dual delivery of drug and bone mineral. Macromol Res 24: 623–628.

46. Lu T, Ma Y, Hu H, et al. (2011) Ethinylestradiol liposome preparation and its effects on ovariectomized rats' osteoporosis. Drug Deliv 18: 468–477.

47. Allen TM, Cullis PR (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliver Rev 65: 36–48.

48. Kundu SK, Sharma AR, Lee SS, et al. (2014) Recent trends of polymer mediated liposomal gene delivery system. Biomed Res Int 2014: 934605–934619.

49. Madni A, Sarfraz M, Rehman M, et al. (2014) Liposomal drug delivery: a versatile platform for challenging clinical applications. Journal Pharm Pharm Sci 17: 401–426.

50. Fang C, Shi B, Pei YY, et al. (2006) In vivo tumor targeting of tumor necrosis factor-α-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci 27: 27–36.

51. Zhang J, Li X, Huang L (2014) Non-viral nanocarriers for siRNA delivery in breast cancer. J Control Release 190: 440–450.

52. Hughes J, Yadava P, Mesaros R (2010) Liposomal siRNA delivery. Meth Mol Biol 605: 445.

53. Ropert C (1999) Liposomes as a gene delivery system. Braz J Med Biol Res 32: 163–169.

54. Hengst V, Oussoren C, Kissel T, et al. (2007) Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 331: 224–227.

55. Vert M, Schwach G, Engel R, et al. (1998) Something new in the field of PLA/GA bioresorbable polymers? J Control Release 53: 85–92.

56. Mooney DT, Mazzoni CL, Breuer C, et al. (1996) Stabilized polyglycolic acid fibre based tubes for tissue engineering. Biomaterials 17: 115–124.

57. Jiang T, Yu X, Carbone EJ, et al. (2014) Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications. Int J Pharm 475: 547–557.

58. Fu YC, Fu TF, Wang HJ, et al. (2014) Aspartic acid-based modified PLGA-PEG nanoparticles for bone targeting: in vitro and in vivo evaluation. Acta Biomater 10: 4583–4596.

59. Cong Y, Quan C, Liu M, et al. (2015) Alendronate-decorated biodegradable polymeric micelles for potential bone-targeted delivery of vancomycin. J Biomat Sci Polym E 26: 629–643.

60. Yi H, Wu LQ, Bentley WE, et al. (2005) Biofabrication with chitosan. Biomacromolecules 6: 2881–2894.

61. Aktaş Y, Andrieux K, Alonso MJ, et al. (2005) Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm 298: 378–383.

62. Schwarz K, Milne D (1972) Growth-promoting effects of Silicon in rats. Nature 239: 333–334.

63. Jugdaohsingh R (2007) Silicon and bone health. J Nutr Health Aging 11: 99–110.

64. Boyce BF, Yao Z, Xing L (2010) Functions of nuclear factor κB in bone. Ann Ny Acad Sci 1192: 367–375.

65. Nanes MS (2003) Tumor necrosis factor-α: molecular and cellular mechanisms in skeletal pathology. Gene 321: 1–15.

66. Yamaguchi M, Neale WM (2012) The intact strontium ranelate complex stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-κB activation. Mol Cell Biochem 359: 399–407.

67. Ha SW, Neale WM, Beck GR (2014) Bioactive silica nanoparticles promote osteoblast differentiation through stimulation of autophagy and direct association with LC3 and p62. ACS Nano 8: 5898–5910.

68. Liu F, Fang F, Yuan H, et al. (2013) Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation. J Bone Miner Res 28: 2414–2430.

69. Baeza A, Manzano M, Colilla M, et al. (2016) Recent advances in mesoporous silica nanoparticles for antitumor therapy: our contribution. Biomater Sci 4: 803–813.

70. Vallet RM, Balas F, Arcos D (2007) Mesoporous materials for drug delivery. Angew Chem 46: 7548–7558.

71. Vallet RM, Rámila A, Del Real RP, et al. (2001) A new property of MCM-41: drug delivery system. Chem Mater 13: 308–311.

72. Sun W, Han Y, Li Z, et al. (2016) Bone-targeted mesoporous silica nanocarrier anchored by zoledronate for cancer bone metastasis. Langmuir 32: 9237–9244.

73. Baeza A, Colilla M, Vallet RM (2015) Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery. Expert Opin Drug Del 12: 319–37.

74. Paris JL, Torre PDL, Manzano M, et al. (2016) Decidua-derived mesenchymal stem cells as carriers of mesoporous silica nanoparticles. in vitro and in vivo evaluation on mammary tumors. Acta Biomater 33: 275–282.

75. Jordan A, Scholz R, Maier HK, et al. (2006) The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neuro-Oncol 78: 7–14.

76. Figuerola A, Di Corato R, Manna L, et al. (2010) From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res 62: 126–143.

77. Choi SY, Song MS, Ryu PD, et al. (2015) Gold nanoparticles promote osteogenic differentiation in human adipose-derived mesenchymal stem cells through the Wnt/beta-catenin signaling pathway. Int J Nanomed 10: 4383–4392.

78. Lee NK, Choi YG, Baik JY, et al. (2005) A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood 106: 852–859.

79. Sul OJ, Kim JC, Kyung TW, et al. (2010) Gold nanoparticles inhibited the receptor activator of nuclear factor-κb ligand (RANKL)-induced osteoclast formation by acting as an antioxidant. Biosci Biotech Bioch 74: 2209–2213.

80. Lean JM, Jagger CJ, Kirstein B, et al. (2015) Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 146: 728–735.

81. Sahana H, Khajuria DK, Razdan R, et al. (2013) Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis. J Biomed Nanotechnol 9: 193–201.

82. Lin L, Chow KL, Leng Y (2009) Study of hydroxyapatite osteoinductivity with an osteogenic differentiation of mesenchymal stem cells. J Biomed Mater Res Part A 89: 326–335.

83. Webster TJ, Ergun C, Doremus RH, et al. (2000) Enhanced functions of osteoblasts on nanophase ceramics. Biomaterials 21: 1803–1810.

84. Yamaguchi M (2010) Role of nutritional zinc in the prevention of osteoporosis. Mol Cell Biochem 338: 241–254.

85. Ito A, Otsuka M, Kawamura H, et al. (2005) Zinc-containing tricalcium phosphate and related materials for promoting bone formation. Curr Appl Phys 5: 402–406.

Copyright Info: © 2017, M. Vallet-Regí, licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)